These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36578356)

  • 1. Idiosyncratic drug-induced liver injury caused by givosiran in a patient with acute intermittent porphyria.
    Ma CD; Faust D; Bonkovsky HL
    Mol Genet Metab Rep; 2023 Mar; 34():100946. PubMed ID: 36578356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idiosyncratic Drug-Induced Liver Injury (DILI) and Herb-Induced Liver Injury (HILI): Diagnostic Algorithm Based on the Quantitative Roussel Uclaf Causality Assessment Method (RUCAM).
    Teschke R; Danan G
    Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33800917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost savings with hemin versus givosiran for the treatment of patients with acute intermittent porphyria (AIP).
    Massachi S; Epstein J; Hurd J; Bonkovsky HL
    J Med Econ; 2020 Dec; 23(12):1441-1449. PubMed ID: 33043761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of Lymphocyte Transformation Test for Assisting Updated Roussel Uclaf Causality Assessment Method in Drug-Induced Liver Injury: A Case-Control Study.
    Rodríguez A; García-García I; Martínez de Soto L; Gómez López De Las Huertas A; Borobia AM; González-Torbay A; Akatbach-Bousaid I; González-Muñoz M; Ramírez E
    Front Pharmacol; 2022; 13():819589. PubMed ID: 35370653
    [No Abstract]   [Full Text] [Related]  

  • 5. Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993-Mid 2020: A Comprehensive Analysis.
    Teschke R; Danan G
    Medicines (Basel); 2020 Sep; 7(10):. PubMed ID: 33003400
    [No Abstract]   [Full Text] [Related]  

  • 6. A revised electronic version of RUCAM for the diagnosis of DILI.
    Hayashi PH; Lucena MI; Fontana RJ; Bjornsson ES; Aithal GP; Barnhart H; Gonzalez-Jimenez A; Yang Q; Gu J; Andrade RJ; Hoofnagle JH
    Hepatology; 2022 Jul; 76(1):18-31. PubMed ID: 35014066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
    Balwani M; Sardh E; Ventura P; Peiró PA; Rees DC; Stölzel U; Bissell DM; Bonkovsky HL; Windyga J; Anderson KE; Parker C; Silver SM; Keel SB; Wang JD; Stein PE; Harper P; Vassiliou D; Wang B; Phillips J; Ivanova A; Langendonk JG; Kauppinen R; Minder E; Horie Y; Penz C; Chen J; Liu S; Ko JJ; Sweetser MT; Garg P; Vaishnaw A; Kim JB; Simon AR; Gouya L;
    N Engl J Med; 2020 Jun; 382(24):2289-2301. PubMed ID: 32521132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Givosiran in acute intermittent porphyria: A personalized medicine approach.
    Poli A; Schmitt C; Moulouel B; Mirmiran A; Talbi N; Rivière S; Cerutti D; Bouchoule I; Faivre A; Grobost V; Douillard C; Duchêne F; Fiorentino V; Dupré T; Manceau H; Peoc'h K; Puy H; Lefebvre T; Gouya L
    Mol Genet Metab; 2022 Mar; 135(3):206-214. PubMed ID: 35058124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent symptoms of acute intermittent porphyria after biochemical normalization with givosiran-An ongoing clinical conundrum.
    Ma CD; Faust D; Bonkovsky HL
    JIMD Rep; 2023 Mar; 64(2):146-149. PubMed ID: 36873084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment?
    Teschke R; Schulze J; Eickhoff A; Danan G
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28398242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case report of a drug-induced liver injury (DILI) caused by multiple antidepressants with causality established by the updated Roussel Uclaf causality assessment method (RUCAM) and in vitro testing.
    González-Muñoz M; Monserrat Villatoro J; Marín-Serrano E; Stewart S; Bardón Rivera B; Marín J; Martínez de Soto L; Seco Meseguer E; Ramírez E
    Clin Case Rep; 2020 Dec; 8(12):3105-3109. PubMed ID: 33363890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Causality Evaluation of Drug-Induced Liver Injury in Newborns and Children in the Intensive Care Unit Using the Updated Roussel Uclaf Causality Assessment Method.
    Ye L; Feng Z; Huang L; Guo C; Wu X; He L; Tan W; Wang Y; Wu X; Hu B; Li T; Yang G; Chengxian G; He Q
    Front Pharmacol; 2021; 12():790108. PubMed ID: 34987403
    [No Abstract]   [Full Text] [Related]  

  • 13. Herb-induced liver injury (HILI) with 12,068 worldwide cases published with causality assessments by Roussel Uclaf Causality Assessment Method (RUCAM): an overview.
    Teschke R; Eickhoff A; Schulze J; Danan G
    Transl Gastroenterol Hepatol; 2021; 6():51. PubMed ID: 34423172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Update on Drug-induced Liver Injury.
    Devarbhavi H
    J Clin Exp Hepatol; 2012 Sep; 2(3):247-59. PubMed ID: 25755441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roussel Uclaf Causality Assessment Method for Drug-Induced Liver Injury: Present and Future.
    Danan G; Teschke R
    Front Pharmacol; 2019; 10():853. PubMed ID: 31417407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019.
    Teschke R
    Front Pharmacol; 2019; 10():730. PubMed ID: 31396080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Report: Lack of Response to Givosiran in a Case of ALAD Porphyria.
    Graff E; Anderson KE; Levy C
    Front Genet; 2022; 13():867856. PubMed ID: 35991568
    [No Abstract]   [Full Text] [Related]  

  • 18. Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Published 2020/2021 Based on RUCAM as Causality Assessment Method.
    Teschke R; Méndez-Sánchez N; Eickhoff A
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highlights of the drug-induced liver injury literature for 2021.
    Woo SM; Alhaqqan DM; Gildea DT; Patel PA; Cundra LB; Lewis JH
    Expert Rev Gastroenterol Hepatol; 2022 Aug; 16(8):767-785. PubMed ID: 35839342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria.
    Sardh E; Harper P; Balwani M; Stein P; Rees D; Bissell DM; Desnick R; Parker C; Phillips J; Bonkovsky HL; Vassiliou D; Penz C; Chan-Daniels A; He Q; Querbes W; Fitzgerald K; Kim JB; Garg P; Vaishnaw A; Simon AR; Anderson KE
    N Engl J Med; 2019 Feb; 380(6):549-558. PubMed ID: 30726693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.